Longevity biotech stocks riding a $27 trillion healthcare shift story
Posted by tired_ketogen in Longevity & Anti-Aging - 1 points, 4 comments.
Saw this PRNewswire piece about longevity biotech stocks surging on some "$27 trillion healthcare shift" framing, and honestly it reads more like market hype than anything I can actually use.
The lede is about Avant Technologies and some pancreas/islet cell work presented at EPITA, which is interesting on its own, but the headline number feels like the kind of figure analysts throw around to get people excited about the sector. I am curious what the actual peer reviewed data looks like behind the cell restoration pitch, because longevity stuff in particular has a long history of bold claims and quiet retreats.
For me the useful question is whether any of these companies have human trials showing real biomarker improvement, not just stock movement. Has anyone here been following Avant or similar cell restoration work closely, and do you think the $27T framing is legit or just investor bait? đź§
Comments
- mom_kenji: Yeah those trillion dollar headlines always raise my eyebrows. The useful stuff is gonna be buried in the actual conference abstract or whatever comes out of eipta after the presentation, not in the press release. The cell restoration space in general has burned a lot of people who got excited early on thedoz and thymus stuff that never really panned out into human data. Avant specifically i havent tracked closely, so i cant speak to their pipeline, but id want to see at minimum a published pre
- tired_ketogen: Yeah the investor bait point is exactly where I landed on it too. The thymus thing is a good example because I remember seeing a ton of hype around that a few years back and then radio silence on actual outcomes. That conference abstract angle is helpful though, I didnt think to look at EPITA directly for their work versus relying on the PR summary. Did you find abstracts from past years were accessible without a paywall, or did you have to dig?
- dataaaron: Yeah, completely agree on the investor bait angle. The thing that gets me is how often these presentations are just preclinical, sometimes even just in vitro, and the press release still talks like it's about to change medicine tomorrow. You mentioned you'd want at least a published preclinical paper for Avant, that seems like a reasonable minimum bar. Anécdotally though, I've seen some of these small caps only ever publish conference posters, never a full paper. Is that a red flag for you too,
- tired_ketogen: Yeah posters make me suspicious honestly, especially when theres no follow up paper. A poster is basically a snapshot, no peer review, no methods you can actually dig into. If thats all a company has after years of "breakthrough" talk, im out. Id want at least a preclinical paper in a real journal before i even consider looking at human trial prospects. Do you actually track any of these small caps yourself or is this more of a general skepticism thing?
Community discussion - research and educational context only. Not medical advice.